CL2017002998A1 - Plantas que tienen expresión modificada de thca sintasa - Google Patents

Plantas que tienen expresión modificada de thca sintasa

Info

Publication number
CL2017002998A1
CL2017002998A1 CL2017002998A CL2017002998A CL2017002998A1 CL 2017002998 A1 CL2017002998 A1 CL 2017002998A1 CL 2017002998 A CL2017002998 A CL 2017002998A CL 2017002998 A CL2017002998 A CL 2017002998A CL 2017002998 A1 CL2017002998 A1 CL 2017002998A1
Authority
CL
Chile
Prior art keywords
plants
modified
expression
invention refers
thca
Prior art date
Application number
CL2017002998A
Other languages
English (en)
Inventor
Ekaterina Alexandra Boudko
Thomas Shipley Iv
Douglas Johnson
Original Assignee
Tweed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tweed Inc filed Critical Tweed Inc
Publication of CL2017002998A1 publication Critical patent/CL2017002998A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y121/00—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21)
    • C12Y121/03—Oxidoreductases acting on X-H and Y-H to form an X-Y bond (1.21) with oxygen as acceptor (1.21.3)
    • C12Y121/03007—Tetrahydrocannabinolic acid synthase (1.21.3.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

<p>LA INVENCIÓN SE REFIERE A NUEVAS PLANTAS GENÉTICAMENTE MODIFICADAS Y MÉTODOS O MATERIALES, TALES COMO POLINUCLEÓTIDOS, CASETES DE EXPRESIÓN, O VECTORES, PARA SU PRODUCCIÓN. ADEMÁS, LA INVENCIÓN SE REFIERE A LA ALTERACIÓN DEL CONTENIDO DE CANNABINOIDES EN PLANTAS, Y A COMPOSICIONES MÉDICAS DERIVADAS DE DICHAS PLANTAS. EN PARTICULARES FORMAS DE REALIZACIÓN, LA PRESENTE INVENCIÓN SE REFIERE A PLANTAS DE CANNABIS QUE TIENEN EXPRESIÓN MODIFICADA DE ÁCIDO TETRAHIDROCANNABINÓLICO (THCA) SINTASA, Y MÉTODOS PARA MODIFICAR LA CANTIDAD DE DELTA-9—TETRAHIDOCANNABINOL (THC) Y CANNABIDIOL (CBD) EN CANNABIS, MODIFICANDO LA EXPRESIÓN DE THCA SINTASA.</p>
CL2017002998A 2015-05-28 2017-11-27 Plantas que tienen expresión modificada de thca sintasa CL2017002998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562167462P 2015-05-28 2015-05-28

Publications (1)

Publication Number Publication Date
CL2017002998A1 true CL2017002998A1 (es) 2018-03-09

Family

ID=57393331

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002998A CL2017002998A1 (es) 2015-05-28 2017-11-27 Plantas que tienen expresión modificada de thca sintasa

Country Status (14)

Country Link
US (2) US10934554B2 (es)
EP (1) EP3302033A4 (es)
JP (1) JP2018519853A (es)
KR (1) KR20180021718A (es)
CN (1) CN107846861A (es)
AU (1) AU2016269328A1 (es)
BR (1) BR112017025388A2 (es)
CA (1) CA2986666A1 (es)
CL (1) CL2017002998A1 (es)
HK (1) HK1252151A1 (es)
IL (2) IL255900B (es)
MX (1) MX2017015304A (es)
RU (1) RU2017146186A (es)
WO (1) WO2016189384A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189384A1 (en) * 2015-05-28 2016-12-01 Tweed Inc. Cannabis plants having modified expression of thca synthase
CA2989194A1 (en) * 2015-06-12 2016-12-15 Anandia Laboratories Inc. Methods and compositions for cannabis characterization
WO2018035450A1 (en) * 2016-08-18 2018-02-22 Ebbu, LLC Plants and methods for increasing and decreasing synthesis of cannabinoids
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CN106591359B (zh) * 2017-02-13 2019-10-25 黑龙江省科学院大庆分院 一种大麻THCA合成酶基因RNAi载体的构建方法
EP3600361A4 (en) 2017-03-24 2021-01-06 Trait Biosciences, Inc. HIGH LEVEL IN VIVO BIOSYNTHESIS AND ISOLATION OF WATER-SOLUBLE CANNABINOIDS IN PLANT SYSTEMS
CA3074510A1 (en) * 2017-10-03 2019-04-11 The Regents Of The University Of Colorado Method for differentiating cannabis plant cultivars based on cannabinoid synthase paralogs
GB2568032B (en) 2017-10-25 2023-03-15 Cell Science Holdings Ltd A method of production of phytocannabinoids for use in medical treatments
US20200347394A1 (en) * 2017-11-02 2020-11-05 Yield10 Bioscience, Inc. Genes and gene combinations for enhanced crops
EP3724322A1 (en) * 2017-12-14 2020-10-21 Medicinal Genomics Corporation Methods and kits for classifying cannabinoid production in cannabis plants
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
HUE060229T2 (hu) * 2018-02-20 2023-02-28 Mymd Pharmaceuticals Inc Genetikailag módosított cannabis sativa növények és módosított kannabinoid vegyületek a kábítószer-függõség és más rendellenességek kezelésére
BR112020020850A2 (pt) 2018-04-09 2021-01-19 Ellevet Sciences Extrato de cânhamo para tratamento da dor em animais
WO2019234754A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Nucleic acid constructs and methods of using same
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) * 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
WO2020035869A1 (en) * 2018-08-17 2020-02-20 Canbreed Ltd. Modulation of cannabinoid profile in cannabis
CN109122306A (zh) * 2018-08-20 2019-01-04 杭州昶胜电子商务有限公司 一种获得高大麻二酚含量工业大麻植株的方法
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
CA3119102A1 (en) * 2018-11-09 2020-05-14 Agriculture Victoria Services Pty Ltd Cannabis plants with a cannabinoid profile enriched for cannabidiol and .delta.-9-tetrahydrocannabinol
US10653085B1 (en) * 2018-12-21 2020-05-19 Charlotte's Web, Inc. Hemp plant named ‘CW1AS1’
WO2020176547A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
WO2020183352A1 (en) * 2019-03-12 2020-09-17 Radient Technologies Innovations Inc. Time specific bioavailability of extract in consumable
CN114025605A (zh) * 2019-04-11 2022-02-08 林家明 一种用于生产转基因种子的方法
US20220304944A1 (en) * 2019-08-23 2022-09-29 Canopy Growth Corporation Methods for reducing thc content in complex cannabinoid mixtures in which thc is a minor component
CN110419397A (zh) * 2019-09-06 2019-11-08 黑龙江汉美生工业大麻科技有限公司 一种提高龙大麻5号cbd含量的种植管理方法
CA3153420A1 (en) * 2019-09-06 2021-03-11 James Berman Genetic modification of plants
IL291837A (en) * 2019-10-01 2022-06-01 Empyrean Neuroscience Inc Genetically modified plants and methods for their preparation
JP2022550585A (ja) * 2019-10-01 2022-12-02 エンピリアン ニューロサイエンス， インコーポレイテッド 遺伝子改変植物及びそれを作製する方法
US20240084270A1 (en) * 2019-10-11 2024-03-14 National University Of Singapore Biosynthesis of cannabinoids from cannabigerolic acid using novel cannabinoid synthases
CN110923242B (zh) * 2019-12-14 2021-04-13 厦门梓蔓生物科技有限公司 一种大麻腺毛中分离的转录因子CsAPL1及其应用
EP3841872A1 (en) 2019-12-28 2021-06-30 Ploidy and Genomics SL. In vitro direct regeneration of polyploid cannabis plants
WO2021138423A1 (en) * 2019-12-30 2021-07-08 Arcadia Biosciences, Inc. Methods for genetically modifying cannabis plants, modified cannabis plants, and products therefrom
CA3175033A1 (en) * 2020-03-10 2021-05-20 Phylos Bioscience, Inc. Autoflowering markers
WO2022013859A1 (en) * 2020-07-13 2022-01-20 Betterseeds Ltd Cannabis with altered cannabinoid content
US20230357785A1 (en) * 2020-09-22 2023-11-09 Growing Together Research Inc. Genetically modified cannabis plants with novel phenotypes
WO2023015268A1 (en) * 2021-08-06 2023-02-09 Phylos Bioscience, Inc. Varin genes
AU2022341127A1 (en) * 2021-09-09 2024-04-18 Agriculture Victoria Services Pty Ltd Methods for the modification of cells, modified cells and uses thereof
CN114214339A (zh) * 2021-12-08 2022-03-22 福建农林大学 一种汉麻thcsas2基因及其编码产物萜烯酚酸氧化环化酶与应用
KR20230143960A (ko) * 2022-04-05 2023-10-13 주식회사 진코어 유전자 교정 단백질을 포함하는 대마 유전자 교정용 조성물 및 이를 이용한 대마 유전자 교정 방법
USPP35571P2 (en) 2023-05-05 2024-01-09 Phat Panda LLC Cannabis plant named ‘AC/DC x Redneck Wedding 13’

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0596979B1 (en) 1991-08-01 2002-01-30 Large Scale Biology Corporation Recombinant plant viral nucleic acids
ATE367809T1 (de) 1998-04-21 2007-08-15 Us Health Cannabinoiden als antioxidantien und neuroschützende mittel
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
WO2003015700A2 (en) 2001-08-15 2003-02-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Novel vasoconstrictor cannabinoid analogs
GB2439393B (en) 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
US9035130B2 (en) * 2007-05-31 2015-05-19 Gw Pharma Limited Reference plant, a method for its production, extracts obtained therefrom and their use
GB2450741A (en) 2007-07-05 2009-01-07 Gw Pharma Ltd Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
US20110257256A1 (en) 2008-07-31 2011-10-20 Bionoria Research Gmbh Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2011017798A1 (en) * 2009-08-12 2011-02-17 National Research Council Of Canada Aromatic prenyltransferase from cannabis
US9611460B2 (en) 2010-04-15 2017-04-04 National Research Council Of Canada Genes and proteins for aromatic polyketide synthesis
US20120311744A1 (en) 2011-06-06 2012-12-06 Erich E. Sirkowski Marked Cannabis For Indicating Medical Marijuana
CN103842509B (zh) 2011-07-13 2016-06-08 加拿大国家研究委员会 用于烷酰基辅酶a合成的基因和蛋白质
US10441617B2 (en) * 2013-03-15 2019-10-15 Biotech Institute, Llc Breeding, production, processing and use of medical cannabis
US9095554B2 (en) * 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US20150098954A1 (en) 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting
US9546960B2 (en) 2014-11-14 2017-01-17 Lightwave Science, Inc. System and method for analysis of cannabis
WO2016189384A1 (en) * 2015-05-28 2016-12-01 Tweed Inc. Cannabis plants having modified expression of thca synthase

Also Published As

Publication number Publication date
IL255900A (en) 2018-01-31
MX2017015304A (es) 2018-07-06
US10934554B2 (en) 2021-03-02
EP3302033A4 (en) 2018-10-31
EP3302033A1 (en) 2018-04-11
BR112017025388A2 (pt) 2018-08-07
KR20180021718A (ko) 2018-03-05
CN107846861A (zh) 2018-03-27
US20180258439A1 (en) 2018-09-13
RU2017146186A (ru) 2019-06-28
US20210207154A1 (en) 2021-07-08
JP2018519853A (ja) 2018-07-26
CA2986666A1 (en) 2016-12-01
IL281500B (en) 2021-12-01
IL281500A (en) 2021-04-29
AU2016269328A1 (en) 2017-12-07
IL255900B (en) 2021-04-29
HK1252151A1 (zh) 2019-05-17
RU2017146186A3 (es) 2019-11-18
WO2016189384A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CL2017002998A1 (es) Plantas que tienen expresión modificada de thca sintasa
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
CO2017004974A2 (es) Extractos de cannabis y métodos de preparación.
CL2017002650A1 (es) Compuestos novedosos
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
BR112019001794A2 (pt) composição de cannabis
CL2018002671A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas del receptor de apelina (apj)
DK3258942T3 (da) Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR102657A1 (es) Composición para tratar telas
EP3268043A4 (en) Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
BR112017027132A2 (pt) reguladores do nrf2
CO7081144A2 (es) Anticuerpos biespecíficos contra tweak humana e il17 humana y usos de los mismos
BR112017013691A2 (pt) composição compreendendo um polímero em multiestágio, seu método de preparação e seu uso
ECSP14013302A (es) Composiciones de yodo-povidona estable
BR112017010177A2 (pt) composição para tratamento de tecido
ES2969970T3 (es) Formas sólidas novedosas
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CU20180045A7 (es) Productos de construcción que comprenden grafeno u óxido de grafeno en el material a granel y método para la producción de tales productos de construcción
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
BR112017021191A2 (pt) um extrato de indigo naturalis e um processo para preparar o mesmo
BR112017021190A2 (pt) composição farmacêutica e o uso da mesma